Non‐alcoholic fatty liver disease
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Summary: Non‐alcoholic fatty liver disease is a clinicopathological condition that comprises a wide spectrum of liver damage, ranging from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. Non‐alcoholic steatohepatitis represents only a stage within the spectrum of non‐alcoholic fatty liver disease and is defined pathologically by the presence of steatosis together with necro‐inflammatory activity. The true prevalence of non‐alcoholic fatty liver disease is unknown, but it is estimated that it affects 10–24% of the general population in different countries. The diagnosis of non‐alcoholic fatty liver disease is based upon convincing evidence of absent or minimal alcohol consumption, compatible histological changes in liver biopsy and the exclusion of other liver diseases. The natural history of non‐alcoholic fatty liver disease remains to be defined. Patients with pure steatosis on liver biopsy follow a relatively benign course, whereas patients with histological necro‐inflammatory changes and/or fibrosis may progress to end‐stage liver disease. An initial step in the treatment of non‐alcoholic fatty liver disease is the management of associated conditions, such as obesity, diabetes mellitus and hyperlipidaemia. Non‐alcoholic fatty liver disease patients with steatohepatitis and/or fibrosis on liver biopsy may benefit from investigational pharmacological therapy. Patients with decompensated cirrhosis from non‐alcoholic fatty liver disease may be candidates for liver transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Powell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473
Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.
Wanless, I. R., & Lentz, J. S. (1990) · Hepatology · doi:10.1002/hep.1840120505 · Cited by 1,191
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., & Diehl, A. M. (2000) · Nature Medicine · doi:10.1038/79697 · Cited by 673
Fatty liver hepatitis and cirrhosis in obese patients
Adler, M., & Schaffner, F. (1979) · The American Journal of Medicine · doi:10.1016/0002-9343(79)90740-x · Cited by 399
Cited by
The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease
McCullough, A. J. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.004 · Cited by 580
Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)
Bellentani, S., & Marino, M. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31820-4 · Cited by 322
Hepatic steatosis in obese patients: clinical aspects and prognostic significance
Festi, D., Colecchia, A., Sacco, T., Bondi, M., Roda, E., & Marchesini, G. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00126.x · Cited by 312
Elevated Liver Function Tests in Type 2 Diabetes
Harris, E. H. (2005) · Clinical Diabetes · doi:10.2337/diaclin.23.3.115 · Cited by 306
Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease
Angelico, F., Del Ben, M., Conti, R., Francioso, S., Feole, K., Fiorello, S., Cavallo, M. G., Zalunardo, B., Lirussi, F., Alessandri, C., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1024 · Cited by 284
Metadata
- Authors
- Alba, L. M., & Lindor, K.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2003-04
- Volume
- 17
- Issue
- 8
- Pages
- 977-986
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2077344442
- Cited by
- 105
- References
- 12
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non‐alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1046/j.1365-2036.2003.01493.x
- The paper
- Alba, L. M., & Lindor, K. (2003). Non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2003.01493.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.